1. Medicines
  2. Neuroscience
  3. KESIMPTA® (ofatumumab)
  4. Downloadable resources

Downloadable Resources

This selection of resources is designed for healthcare professionals to support patients with relapsing forms of multiple sclerosis (RMS) throughout their KESIMPTA® (ofatumumab) journey.

You can download these materials and share them with your healthcare team and patients.

Getting Started with KESIMPTA®

A guide to support you in initiating KESIMPTA® for patients switching from oral therapies, self-administered injectables or I/V infusions.

Download

Click & Go with KESIMPTA®

A guide to support you in educating
your patients on administering
KESIMPTA® with the Senoready® Pen.

Download

KESIMPTA® Patient Booklet

This booklet provides useful information for patients starting treatment with KESIMPTA®, including how to take KESIMPTA®, how to store KESIMPTA® and important treatment information.

Download

KESIMPTA® Adherence Diary

This is an adherence diary to ensure that patients are getting the most out of their KESIMPTA® treatment by helping them to track their injection days and to follow the dosing schedule exactly as prescribed

Download

Click here for Product Information

References:
  1. KESIMPTA® SPC available at www.medicines.ie last accessed July 2022
  2. Smith P, et al. Presented at ECTRIMS 2016;P1143.
  3. Pacheco-Fernandez T, et al. Presented at AAN 2018, S52.003.
  4. Gupta I, Jewell R. Ofatumumab, the first human anti-CD20 monoclonal antibody for the treatment of B cell hematologic malignancies.
  5. Huck C, Leppert D, Wegert V, et al. Low-dose subcutaneous anti-CD20 treatment depletes disease relevant B cell subsets and attenuates neuroinflammation. J Neuroimmune Pharmacol. 2019;14(4):709-719.
  6. Torres JB, Roodselaar J, Sealey M, et al. Distribution and efficacy of ofatumumab and ocrelizumab in humanized-CD20 mice following subcutaneous or intravenous administration. Poster P2.2.052. Presented at: American Academy of Neurology Annual Meeting; May 4-10, 2019; Philadelphia, PA.
  7. Theil D, Smith P, Huck C, et al. Imaging mass cytometry and single-cell genomics reveal differential depletion and repletion of B-cell populations following ofatumumab treatment in cynomolgus monkeys. Front lmmunol. 2019;10:1-11.
  8. Hauser SL, Bar-Or A, Cohen JA, et al. B-cell depletion and efficacy outcomes with ofatumumab: subgroup analysis from the pooled phase 3 ASCLEPIOS I and II trials. Poster P7.1- 013. Presented at: American Academy of Neurology Annual Meeting; 2020; Philadelphia, PA.
  9. Hauser SL, Bar-Or A, Cohen JA, et al; for the ASCLEPIOS I and ASCLEPIOS II trial groups. Ofatumumab versus teriflunomide in multiple sclerosis [supplemental appendix]. N Engl J Med. 2020;383(6):546-557.
  10. Hauser SL, Bar-Or A, Cohen JA, et al; for the ASCLEPIOS I and ASCLEPIOS II trial groups. Ofatumumab versus teriflunomide in multiple sclerosis N Engl J Med. 2020;383(6):546-557.
  11. Hauser SL, et al. Ofatumumab vs Teriflunomide in Relapsing Multiple Sclerosis: Analysis of No Evidence of Disease Activity (NEDA-3) from ASCLEPIOS I and II Trials Presented at EAN 2020. LB62
  12. Data on file. OMB157G (ofatumumab) Statistical overview. Novartis Pharmaceuticals Corp; East Hanover, NJ. December 2019
  13. Giovannoni G, Turner B, Gnanapavan S, Offiah C, Schmierer K, Marta M. Is it time to target no evident disease activity (NEDA) in multiple sclerosis? Mult Scler Relat Disord. 2015;4(4):329-333.
  14. de Seze J, Bar-Or A, Correale J, et al. Effect of ofatumumab on serum immunoglobulin levels and infection risk in relapsing multiple sclerosis patients from the phase 3 ASCLEPIOS I and II trials. Presented at: the 6th Congress of the European Academy of Neurology; May 23-26, 2020; Virtual Congress.
Rate this content: 
No votes yet
IE224173 July 2022
Print
▼ This medicinal product is subject to additional monitoring. Reporting suspected adverse reactions of the medicinal product is important to Novartis and the HPRA. It allows continued monitoring of the benefit/risk profile of the medicinal product. All suspected adverse reactions should be reported via HPRA Pharmacovigilance, website: www.hpra.ie. Adverse events could also be reported to Novartis preferably via www.report.novartis.com or by email: [email protected] or by calling 01 2080 612.
×

Ask Speakers

×

Medical Information Request